TIGECYCLINE-INDUCED ACUTE PANCREATITIS: ABOUT TWO CASES AND REVIEW OF THE LITERATURE

REFERENCES

• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections, Clin Infect Dis 2005; 41(5) (2005): 5303–5314.
   Google Scholar
• Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470–480.
   PubMed Web of Science ®Google Scholar
• Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Cllis-Grosse E et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase III randomized double-blind trial. Int JInfect Dis 2005; 9:251–261.
   PubMed Web of Science ®Google Scholar
• Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasnaand T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of skin and skin-structure infections: results of 2 double - blind phase III comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother 2005; 49:4658–4666.
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse Ej, Babinschak T, dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase III comparison studies with vancomycin-aztreonam. Clin Inf Dis 2005; 41\(suppl 5): 5341–353.
   Google Scholar
• Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tige-cycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220–229.
   PubMed Web of Science ®Google Scholar
• Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of antibacterial resistance. Micro biol Mol Biol Rev 2001; 65: 232–260.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Homenuik k, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines, a comparative review with tetracyclines. Drugs 2004; 64: 63–68.
   PubMed Web of Science ®Google Scholar
• Gilson M, Moachon L, Jeanne L, Dumaine V, Eyrolle L, Morand P, et al. Acute pancreatitis related to tigecycline: case report and review of the literature. Scand J Infect Dis 2008; 40: 681–683.
   PubMed Web of Science ®Google Scholar
• Lipshitz J, Kruh J, Cheung P, Cassagnol M. Tigecycline-induced pancreatitis. J Clin Gastroenterol 2009; 43: 93.
   Web of Science ®Google Scholar
• Marshall SR. Tigecycline-induced pancreatitis, Hosp Pharm 2009; 44: 239–241.
   Google Scholar
• Hung WY, Kogelman L, Volpe G, lafrati M, Davidson L. Tigecycline-induced pan-creatitis: case report and literature revizw. Int Journal of Antimicrobiol Agents 2009; 34:486–489.
   PubMed Web of Science ®Google Scholar
• Prot-Labarthe, Youdaren R, Benkerrou M, Basmaci R, Lorrot M. Pediatric acute pancreatitis related to tigecycline. The pediatric infectious disease Journal, 2010; 29: 890–891.
   PubMed Web of Science ®Google Scholar
• McArthur KE. Review article: drug-induced pancreatitis. Aliment Pharmacol Then 1996; 10(1): 23–38.
   Web of Science ®Google Scholar
• Trivedi et al. Drug-induced pancreatitis: an update, J Clin Gastroenterol 2005; 39(8): 709–716.
   PubMed Web of Science ®Google Scholar
• Wyeth Pharmaceutics. Tygacil (package insert). Philadelphia, PA: Wyeth Pharmaceutics; 2009.
   Google Scholar
• Badalov N et al. Drug-induced acute pancreatitis: an evidence-based review, Clinical Gastroenterology and Hepatology 2007; 5: 648–661.
   PubMed Web of Science ®Google Scholar
• Mallory A, Kern F Jr. Drug-induced pancreatitis: a critical review. Gastroenterol-ogy 1980; 78: 813–820.
   PubMed Web of Science ®Google Scholar
• Steinberg WM, Acute drug and toxin induced pancreatitis. Hosp Pract 1985; 20: 95–102.
   Web of Science ®Google Scholar
• Elmore MF, Rogge JD. Tetracycline-induced pancreatitis. Gastroenterology 1981; 81:1134–1136.
   Web of Science ®Google Scholar
• Nicolau DP, Mengedoht DE, Kline JJ. Tetracycline-induced pancreatitis. Am J Gastroenterol 1991; 86(11): 1669–1671.
   Web of Science ®Google Scholar
• Unpublished observations. Tygacyl, Second Periodic Safety Update Report-Preliminary assessment report. Rapporteur: Calvo G. Pharmacovigilance asses-sors: Macia Ma, Martin-Serrano G. Clinical assessors: Fernandez-Cortizo MJ. Period cover by this PSUR: 15 juin 2006 to 14 december 2006. Date of the assessment report: 17 April 2007.
   Google Scholar
• Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al. Effi-cacy and safety of tigecycline compared with vancomycin or linezolid for treat-ment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicenter, double-blind, ran-domized study. J Antimicrob Chemother 2008; 62(51): i17–i28.
   Google Scholar
• Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, et al. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneu-moniae. J Antimicrob Chemother 2008; 62(51): i29–i40.
   Google Scholar
• Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, Wouters L, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneu-monia: results from a double-blind randomized Phase 3 comparison study with levofloxacin. Diagn Microbial Infect Dis 2009; 63: 52–61.
   PubMed Web of Science ®Google Scholar
• Cai Y, et al. Systemic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for the Treatment of Infectious Diseases. AAC 2011; 55(3): 1162–1172.
   Web of Science ®Google Scholar